Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios-Athanasios Dimopoulos

Showing results (251-260 of 283) with videos related to

Pageof 29
Sort By:
American Journal of Hematology|October 24, 2025
Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast NephropathyHeinz Ludwig, Meletios Athanasios Dimopoulos, Evangelos Terpos, et al.
European Heart Journal. Cardiovascular Imaging|August 18, 2022
Cardiac mechanics in response to proteasome inhibition: a prospective studyNikolaos Makris, Georgios Georgiopoulos, Aggeliki Laina, et al.
American Journal of Hematology|July 2, 2024
Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study GroupEirini Katodritou, Dimitra Dalampira, Sosana Delimpasi, et al.
Blood|December 4, 2015
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentPaul G Richardson, Vânia T M Hungria, Sung-Soo Yoon, et al.
Clinical Genitourinary Cancer|February 3, 2020
Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line ChemotherapyAristotelis Bamias, Kimon Tzannis, Ioannis Dimitriadis, et al.
American Journal of Hematology|March 4, 2023
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study groupEirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, et al.
Current Medicinal Chemistry|November 18, 2021
Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary <i>In Silico</i>, <i>In Vitro</i> and <i>In Vivo</i> InvestigationAnastasios I Birmpilis, Panagiotis Vitsos, Ioannis V Kostopoulos, et al.
The Lancet. Haematology|October 4, 2023
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised studyMeletios Athanasios Dimopoulos, Vania T M Hungria, Atanas Radinoff, et al.
The Lancet. Haematology|January 15, 2022
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 studyFredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, et al.
Current Oncology (Toronto, Ont.)|September 22, 2022
Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational StudyAristotelis Bamias, Kimon Tzannis, Roubini Zakopoulou, et al.
Pageof 29

Showing results (251-260 of 283) with videos related to

Sort By:
Pageof 29
American Journal of Hematology|October 24, 2025
Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast NephropathyHeinz Ludwig, Meletios Athanasios Dimopoulos, Evangelos Terpos, et al.
European Heart Journal. Cardiovascular Imaging|August 18, 2022
Cardiac mechanics in response to proteasome inhibition: a prospective studyNikolaos Makris, Georgios Georgiopoulos, Aggeliki Laina, et al.
American Journal of Hematology|July 2, 2024
Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study GroupEirini Katodritou, Dimitra Dalampira, Sosana Delimpasi, et al.
Blood|December 4, 2015
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentPaul G Richardson, Vânia T M Hungria, Sung-Soo Yoon, et al.
Clinical Genitourinary Cancer|February 3, 2020
Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line ChemotherapyAristotelis Bamias, Kimon Tzannis, Ioannis Dimitriadis, et al.
American Journal of Hematology|March 4, 2023
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study groupEirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, et al.
Current Medicinal Chemistry|November 18, 2021
Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary <i>In Silico</i>, <i>In Vitro</i> and <i>In Vivo</i> InvestigationAnastasios I Birmpilis, Panagiotis Vitsos, Ioannis V Kostopoulos, et al.
The Lancet. Haematology|October 4, 2023
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised studyMeletios Athanasios Dimopoulos, Vania T M Hungria, Atanas Radinoff, et al.
The Lancet. Haematology|January 15, 2022
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 studyFredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, et al.
Current Oncology (Toronto, Ont.)|September 22, 2022
Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational StudyAristotelis Bamias, Kimon Tzannis, Roubini Zakopoulou, et al.
Pageof 29